BioCentury | Aug 17, 2017

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
BioCentury | Sep 29, 2014

Avalon-GSK bet on familiarity, speed

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Avalon Ventures' double launch of iron play Silarus Therapeutics Inc. and autoimmune company Thyritope Biosciences Inc. shows one more element the pharma likes about the partnership's 2013 deal to fund...
BioCentury | Jul 17, 2014
Distillery Therapeutics

Indication: Hematology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Thalassemia Family with sequence similarity 132 b (FAM132b; erythroferrone; myonectin) Mouse studies suggest erythroferrone antagonists could be useful for treating iron overload from blood transfusions...
BioCentury | Feb 23, 2012
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...diabetes. Insulin-resistant obese mice had less Ctrp12 expression in fat pads and lower levels of Ctrp12... serum than lean mice. In genetic and diet-induced models of obesity, adenoviral-mediated expression of Ctrp12...
...seen using a control adenoviral vector. Next steps could include identifying the mechanism involved in CTRP12-mediated...
Items per page:
1 - 4 of 4